NEW YORK,Oct. 26 (GenomeWeb News) - Shares in CombiMatrix were up 79.7 percent, or $1.10, at $2.48 in mid-afternoon trading after the company launched an influenza DNA microarray.
According to CombiMatrix, the microarray can identify H5N1 bird flu and influenza A strains as well as provide information on mutations and unknown strains.
CombiMatrix's Influenza Microarray is included in its CatalogArray product line. It can detect and accurately type flu strains using a protocol that requires fewer than four hours, the company said. It is also designed to work on samples from humans, birds, pigs, horses, dogs, and other animals.
CombiMatrix is offering the system as a tool or as a service to researchers, and is also developing it as a field-deployable biodetector using electrochemical techniques.